Applied therapeutics to host diabetic cardiomyopathy expert forum with key opinion leaders on tuesday, november 7

Forum to be webcast live topline phase 3 data readout from arise-hf trial of at-001 (caficrestat) in diabetic cardiomyopathy on track for 4q 2023 new york, nov. 01, 2023 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will host a diabetic cardiomyopathy (dbcm) expert forum with key opinion leaders on tuesday, november 7, 2023 at 8:00 a.m. et. members of the company's senior management team will be joined by the following key opinion leaders: james januzzi, md, hutter family professor of medicine, harvard medical school; director, dennis and marilyn barry fellowship in cardiology research, massachusetts general hospital gregory lewis, md, director, cardiopulmonary exercise testing laboratory and section head, heart failure, massachusetts general hospital the agenda for the event is as follows: diabetic cardiomyopathy disease overview & treatment landscape (dr. januzzi) arise-hf registrational phase 3 trial overview (dr. januzzi) cardiac functional capacity (primary endpoint in arise-hf) (dr. lewis) q&a (with drs.
APLT Ratings Summary
APLT Quant Ranking